CSPC Pharmaceutical Group... (CHJTF)
OTC: CHJTF
· Real-Time Price · USD
1.27
0.00 (0.00%)
At close: Aug 05, 2025, 12:35 PM
CSPC Pharmaceutical Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 6.78B | n/a | 9B | n/a | 13.23B | 10.47B | 11.56B | 10.62B | 11.36B | 9.72B |
Short-Term Investments | 1.47B | n/a | 2.62B | n/a | 1.19B | 1.63B | 4.01B | 5.09B | 1.77B | 3.59B |
Long-Term Investments | 4.8B | n/a | 6.93B | n/a | 5.13B | 3.03B | 4.25B | 3.93B | 4.42B | 4.24B |
Other Long-Term Assets | 1.53B | n/a | 1.39B | n/a | 245.79M | 2.25B | 630.6M | 646.66M | 513.63M | 237.43M |
Receivables | 9.94B | n/a | 12.3B | n/a | 10.68B | 9.48B | 7.62B | 7.01B | 7.98B | 6.93B |
Inventory | 3.13B | n/a | 3.72B | n/a | 3.46B | 2.75B | 2.87B | 3.08B | 3.03B | 2.2B |
Other Current Assets | 362.35M | -11.98B | 798.3M | -14.92B | -2.71B | 9.54B | 6.84B | 6.23B | 6.55B | 5.8B |
Total Current Assets | 21.89B | n/a | 28.44B | n/a | 26.74B | 24.38B | 26.9B | 26.76B | 24.88B | 22.98B |
Property-Plant & Equipment | 13.08B | n/a | 12.23B | n/a | 13.5B | 11.36B | 12.32B | 11.81B | 11.7B | 11.02B |
Goodwill & Intangibles | 2.84B | n/a | 2.47B | n/a | 2.43B | 2.5B | 2.67B | 2.24B | 939.25M | 912.58M |
Total Long-Term Assets | 22.5B | n/a | 23.03B | n/a | 21.51B | 19.29B | 20B | 18.77B | 17.62B | 16.51B |
Total Assets | 44.39B | n/a | 51.47B | n/a | 46.28B | 43.67B | 46.9B | 45.53B | 42.5B | 39.48B |
Account Payables | 2.61B | n/a | 3.47B | n/a | 2.84B | 2.36B | 2.01B | 1.79B | 1.62B | 1.48B |
Deferred Revenue | n/a | n/a | n/a | n/a | 359.15M | 251.91M | 897.58M | 299M | 524.05M | 395.42M |
Short-Term Debt | 392.2M | n/a | 217.66M | n/a | 450.22M | 55.37M | 331.83M | 384.58M | n/a | n/a |
Other Current Liabilities | 945.86M | n/a | 7.39B | n/a | 127.44M | 233.51M | 1.86B | 1.71B | 2.26B | 1.73B |
Total Current Liabilities | 9.63B | n/a | 11.21B | n/a | 10.18B | 9.03B | 10.06B | 9.92B | 8.84B | 8.32B |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | 19.9M | 28.95M | 11.79M | n/a | n/a |
Other Long-Term Liabilities | 407.81M | -40.4B | 991.13M | -37.95B | 399.68M | 372.32M | 110.34M | 408.61M | 97.59M | 330.79M |
Total Long-Term Liabilities | 888.67M | -40.4B | 1.06B | -37.95B | 1.08B | 1.14B | 1.01B | 1.13B | 534.69M | 750.51M |
Total Liabilities | 10.52B | -40.4B | 12.28B | -37.95B | 11.26B | 10.16B | 11.07B | 11.05B | 9.37B | 9.07B |
Total Debt | 507.33M | n/a | 417.85M | n/a | 706.9M | 415.26M | 654.05M | 800.09M | 115.04M | 185.7M |
Common Stock | 11.03B | n/a | 11.83B | n/a | 12B | 10.9B | 12.24B | 12.78B | 13.33B | 13.1B |
Retained Earnings | 23.34B | n/a | 29.3B | n/a | 24.03B | 22.86B | 23.73B | 22.49B | 21.13B | 18.87B |
Comprehensive Income | -4.68B | 38.61B | -3.55B | 35.99B | -1.56B | -1.73B | -1.97B | -2.3B | -2.57B | -2.4B |
Shareholders Equity | 32.26B | 40.4B | 37.45B | 37.95B | 36.56B | 31.82B | 33.9B | 32.87B | 31.79B | 29.45B |
Total Investments | 6.27B | n/a | 9.55B | n/a | 6.31B | 4.66B | 8.26B | 9.02B | 6.18B | 7.82B |